Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Chapple

Showing results (91-100 of 166) with videos related to

Pageof 17
Sort By:
BJU International|April 21, 2005
A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladderChristopher Chapple, William Steers, Peggy Norton, et al.
European Urology|April 19, 2011
The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an updateAnastasios Athanasopoulos, Christopher Chapple, Clare Fowler, et al.
Current Medical Research and Opinion|March 24, 2015
Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic reviewChristopher Chapple, Matthias Oelke, Steven A Kaplan, et al.
The Journal of Physiology|December 4, 2013
Age-related changes in afferent pathways and urothelial function in the male mouse bladderDonna M Daly, Linda Nocchi, Marina Liaskos, et al.
BJU International|February 21, 2014
Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trialChristopher Chapple, Tim Schneider, François Haab, et al.
European Urology|June 20, 2006
Characteristics of patients presenting with LUTS/BPH in six European countriesAnnie Hutchison, Richard Farmer, Christopher Chapple, et al.
Urology|January 14, 2014
SIU/ICUD Consultation on Urethral Strictures: The management of anterior urethral stricture disease using substitution urethroplastyChristopher Chapple, Daniela Andrich, Anthony Atala, et al.
European Urology|March 3, 2017
European Association of Urology Position Statement on the Role of the Urologist in the Management of Male Hypogonadism and Testosterone TherapyVincenzo Mirone, Frans Debruyne, Gert Dohle, et al.
Neurourology and Urodynamics|February 23, 2025
Do We Have the Evidence to Produce Tools to Enable the Identification and Personalization of Management of Women's Pelvic Floor Health Disorders Through the Perinatal and Perimenopausal Periods? ICI-RS 2024Rohna Kearney, Stefano Salvatore, Vik Khullar, et al.
Neurourology and Urodynamics|July 8, 2024
Efficacy and safety of onabotulinumtoxinA for the treatment of overactive bladder in men and women: A pooled analysisVictor W Nitti, Alfred Kohan, Kurt McCammon, et al.
Pageof 17

Showing results (91-100 of 166) with videos related to

Sort By:
Pageof 17
BJU International|April 21, 2005
A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladderChristopher Chapple, William Steers, Peggy Norton, et al.
European Urology|April 19, 2011
The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an updateAnastasios Athanasopoulos, Christopher Chapple, Clare Fowler, et al.
Current Medical Research and Opinion|March 24, 2015
Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic reviewChristopher Chapple, Matthias Oelke, Steven A Kaplan, et al.
The Journal of Physiology|December 4, 2013
Age-related changes in afferent pathways and urothelial function in the male mouse bladderDonna M Daly, Linda Nocchi, Marina Liaskos, et al.
BJU International|February 21, 2014
Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trialChristopher Chapple, Tim Schneider, François Haab, et al.
European Urology|June 20, 2006
Characteristics of patients presenting with LUTS/BPH in six European countriesAnnie Hutchison, Richard Farmer, Christopher Chapple, et al.
Urology|January 14, 2014
SIU/ICUD Consultation on Urethral Strictures: The management of anterior urethral stricture disease using substitution urethroplastyChristopher Chapple, Daniela Andrich, Anthony Atala, et al.
European Urology|March 3, 2017
European Association of Urology Position Statement on the Role of the Urologist in the Management of Male Hypogonadism and Testosterone TherapyVincenzo Mirone, Frans Debruyne, Gert Dohle, et al.
Neurourology and Urodynamics|February 23, 2025
Do We Have the Evidence to Produce Tools to Enable the Identification and Personalization of Management of Women's Pelvic Floor Health Disorders Through the Perinatal and Perimenopausal Periods? ICI-RS 2024Rohna Kearney, Stefano Salvatore, Vik Khullar, et al.
Neurourology and Urodynamics|July 8, 2024
Efficacy and safety of onabotulinumtoxinA for the treatment of overactive bladder in men and women: A pooled analysisVictor W Nitti, Alfred Kohan, Kurt McCammon, et al.
Pageof 17